Pensionfund Sabic Buys $1.83M Stake in Eli Lilly

The fund purchased 1,700 shares of the pharmaceutical company's stock in Q4 2025.

Mar. 27, 2026 at 9:55am

Got story updates? Submit your updates here. ›

Pensionfund Sabic, a pension fund, purchased a new position in Eli Lilly and Company (NYSE:LLY) during the fourth quarter of 2025. The fund acquired 1,700 shares of the pharmaceutical company's stock, valued at approximately $1.83 million.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, developing and commercializing a broad range of medicines and therapies globally. This investment by Pensionfund Sabic signals confidence in Eli Lilly's future growth and profitability.

The details

Pensionfund Sabic's new position in Eli Lilly was part of a broader trend of institutional investors increasing their stakes in the company. Other major shareholders include Vanguard Group, State Street Corp, and Capital Research Global Investors, all of whom raised their positions in Eli Lilly during the same quarter.

  • Pensionfund Sabic purchased the 1,700 Eli Lilly shares in Q4 2025.

The players

Pensionfund Sabic

A pension fund that purchased a new $1.83 million position in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures and commercializes a broad range of medicines and therapies worldwide.

Vanguard Group

A major institutional investor that raised its position in Eli Lilly during Q4 2025.

State Street Corp

A major institutional investor that raised its position in Eli Lilly during Q4 2025.

Capital Research Global Investors

A major institutional investor that raised its position in Eli Lilly during Q4 2025.

Got photos? Submit your photos here. ›

The takeaway

Eli Lilly's strong performance and growth potential continue to attract major institutional investors like Pensionfund Sabic, signaling confidence in the company's future prospects within the pharmaceutical industry.